BenevolentAI
BAI | AS
Overview
Corporate Details
- ISIN(s):
- LU2355630455
- LEI:
- 2221003P54KEDC3P4Z33
- Country:
- United Kingdom
- Address:
- 4-8 Maple Street, W1T 5HD London
- Website:
- https://www.benevolent.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
BenevolentAI is a leading clinical-stage artificial intelligence (AI) company specializing in drug discovery and development. Headquartered in London, BenevolentAI leverages cutting-edge AI and machine learning technologies to accelerate the identification of novel drug candidates, optimize clinical trial success, and address critical unmet medical needs. With its proprietary platform, the company integrates vast biomedical data with advanced computational techniques to uncover insights into disease mechanisms and therapeutic pathways. BenevolentAI collaborates with pharmaceutical and biotechnology partners worldwide, driving innovation to improve healthcare outcomes and advance the future of medicine.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-03-12 12:12 |
Delisting Announcement
BAI EGM Results APPROVED
|
English | 169.9 KB | |
| 2025-02-06 07:00 |
Delisting Announcement
Merger-Delisting and Notice of EGM FINAL APPROVED copy
|
English | 95.2 KB | |
| 2024-12-11 13:17 |
Delisting Announcement
BenevolentAI unveils major strategic overhaul with return to original mission
|
English | 440.5 KB | |
| 2024-12-11 07:00 |
Delisting Announcement
241211_BenevolentAI Statement_FINAL
|
English | 440.5 KB | |
| 2024-12-03 13:36 |
Share Issue/Capital Change
Regulatory Announcement - Issue of Equity and TVR (RSU Settlement) 03122024
|
English | 111.3 KB | |
| 2024-10-17 07:00 |
Board/Management Information
241017 BenevolentAI_Leadership update_Final
|
English | 384.6 KB | |
| 2024-09-23 14:15 |
Major Shareholding Notification
Major Shareholding Notification (LINK) - 13 September 2024 rev
|
English | 494.2 KB | |
| 2024-09-19 07:00 |
Interim Report
240919_BAI Interims 24 press release_FINAL
|
English | 468.9 KB | |
| 2024-07-30 12:56 |
Director's Dealing
PDMR Notification - Dr. Joerg Moeller
|
English | 56.6 KB | |
| 2024-07-03 07:00 |
Board/Management Information
BAI_LEADERSHIP TEAM CHANGE_FINAL_03.07.2024
|
English | 140.6 KB | |
| 2024-05-02 15:30 |
Post-Annual General Meeting Information
AGM Results 2 May 2024 FINAL
|
English | 129.2 KB | |
| 2024-05-01 12:37 |
Major Shareholding Notification
Major Holdings Notification (Annex A) ABG-ODY-BAI LIMITED
|
English | 62.7 KB | |
| 2024-04-23 07:00 |
Regulatory News Service
Business Update 23 April 24 FINAL
|
English | 166.2 KB | |
| 2024-04-17 07:00 |
Pre-Annual General Meeting Information
BAI_Publication of the Revised Agenda for the 2024 AGM_FINAL_17.04.24
|
English | 69.7 KB | |
| 2024-04-15 07:00 |
Board/Management Information
BAI_PROPOSED CHANGES TO BOARD COMPOSITION _FINAL_15.04.24
|
English | 168.4 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Cyclezyme AB | Sweden | CYCLE | |
|
Cyxone AB | Sweden | CYXO | |
|
DBV Technologies | France | DBV | |
|
DEINOVE | France | ALDEI | |
|
Deutsche Biotech Innovativ AG | Germany | DBI | |
|
Devyser Diagnostics | Sweden | DVYSR | |
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
|
Diamyd Medical AB (publ) | Sweden | DMYD | |
|
Diasorin | Italy | DIA | |
| DNA Group (T.R.) Ltd. | Israel | DNA | ||
|
Double Bond Pharmaceutical International AB | Sweden | DBP B |